Pre-pandemic cancer death rates were trending downward at an encouraging rate. However, global instability from COVID-19 has resulted in disruption to vital cancer screenings and treatment.
Precision’s Jennifer Williams and Dominic Galante analyze the pandemic’s impact on cancer care and discuss how it could help usher in some practices that may lead to future improvements in cancer screening, treatment and care for patients.
Read the full article here!
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
